VTRS Q1 2021 Earnings — Viatris Inc. Revenue & Financial Results | Market Cap Arena

VTRSViatris Inc.

$17B

Q1 2021 Earnings

Healthcare Drug Manufacturers - Specialty & Generic

Income Statement

Revenue

$4.4B+69.1% YoY

Gross Profit

$1.1B25.4% margin

Operating Income

-$266M-6.0% margin

Net Income

-$1.0B-23.4% margin

EPS (Diluted)

$-0.86

QoQ Revenue Growth

+22.3%

Cash Flow

Operating Cash Flow

$849M

Free Cash Flow

$796M

Stock-Based Comp.

$33M

Balance Sheet

Total Assets

$59.0B

Total Liabilities

$37.6B

Stockholders' Equity

$21.4B

Cash & Equivalents

$807M

Year-over-Year Comparison

Metric	Current	Year Ago	Change
Revenue	$4.4B	$2.6B	+69.1%
Gross Profit	$1.1B	$906M	+24.4%
Operating Income	-$266M	$185M	-244.1%
Net Income	-$1.0B	$21M	-5088.5%

Revenue Segments

Brands

$2.7B62%

Generics

$1.3B31%

Complex GX and Biosimilars

$329M7%

Geographic Segments

Developed Markets Segment

$2.6B58%

Emerging Markets Segment

$755M17%

Greater China Segment

$592M13%

Japan, Australia and New Zealand Segment

$482M11%